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Abstract: Cats are the primary reservoir host for Bartonella henselae (B. henselae), an etiological agent
of human bartonellosis, including cat scratch disease. Although Bartonella DNA has been amplified
from salivary swabs from cats, dogs and humans, we are not aware of studies investigating Bartonella
antibodies in oral fluid (OF). Using inhouse and commercial immunofluorescence antibody assays
(IFA), the objective of this study was to detect and compare antibodies against B. henselae in paired
OF and serum specimens from cats. Specimens were collected from shelter and client-owned cats.
For serum specimens, B. henselae seroreactivity was 78% for both the inhouse and commercial IFA
assays and 56.8% for OF specimens. Comparing serum and OF specimens, there was moderate
Kappa agreement (Cohen’s k = 0.434) for detection of B. henselae antibodies. Oral fluid antibodies
were more likely measurable in cats with high B. henselae serum antibody titers when compared with
low antibody titers. In conclusion, B. henselae OF IFA antibody measurements were less sensitive
compared to serum IFA measurements of ≥1:64. Oral fluid antibodies were detected more often in
cats with high B. henselae serum antibody titers. Therefore, OF antibodies, detectable by IFA, is of
limited utility for epidemiological or diagnostic testing in cats.
Keywords: bartonellosis; feline; serology; immunofluorescence antibody assay; oral fluid
1. Introduction
Cats are the primary reservoir for B. henselae, the etiological agent of human cat scratch
disease, and a major cause of bartonellosis across animal species [1,2]. Bartonella henselae is
considered a stealth pathogen, particularly in dogs and humans, where published data is
expanding the spectrum of clinical manifestations that have been historically associated
with this infection [3].
For clinicians and researchers, documentation of Bartonella infection in most animal
species remains a challenge due to the lack of sensitive and/or specific testing modalities.
Testing limitations apply to diagnostic assays used to evaluate cats, dogs and humans
for indirect (antibody) or direct (culture, antigen, DNA) evidence of Bartonella spp. infec-
tions [4–6]. Despite a wide variety of currently available commercial and research testing
modalities, a negative serological or direct detection test result does not guarantee the
absence of this stealth pathogen [7–9]. The combination of a thorough clinical data analysis,
including age, sex, animal and arthropod vector exposure history, physical examination
findings, ancillary laboratory testing, in conjunction with indirect and direct diagnostic
microbiological techniques is the most effective strategy for the diagnosis of Bartonella spp.
infections [6,10,11].
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The immunofluorescence antibody assay (IFA) is the most widely employed serologi-
cal technique to measure Bartonella spp. IgM or IgG antibodies in patient sera [12]; however,
Enzyme-Linked Immunosorbent Assays (ELISA) [13] and Western immunoblot assays
are also commercially available [14]. Seronegativity is an important limitation during
early acute infection and in a subset of animal and human patients during longstanding
bloodstream infections [15,16]. In the context of direct detection, PCR is the most frequently
used molecular assay to detect the presence of Bartonella spp. DNA in patient specimens,
including whole blood, fresh or frozen tissue, lymph node aspirates and saliva [17,18].
Combining enrichment culture prior to PCR testing is a diagnostic strategy developed
to optimize the documentation of “active” infection [19]. Moreover, low and potentially
relapsing bacteremia rates may represent limiting factors for the sensitivity of PCR and
enrichment blood culture/PCR techniques. Noninvasive specimens, such as saliva, have
been analyzed using PCR to detect Bartonella spp. DNA in cats [20,21]. Oral fluids (OF)
include whole saliva, fractionated saliva, gingival crevicular fluid, and dentinal tubular
fluid [22]. Therefore, oral fluid samples include not only saliva but also crevicular and
dentinal tubular fluids, which we refer to collectively as OF in this study. To our knowledge,
OF has not been used for the detection of antibodies against B. henselae antigens in cats.
Salivary IgG originates via gingival transudation from the capillary network below the oral
mucosa [23]. Documentation of salivary IgG offers clinicians and researchers the possibility
to obtain an alternative diagnostic specimen for the detection of Bartonella-specific antibod-
ies. Saliva has been used previously as the diagnostic specimen for detecting antibodies
against feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) in cats [24,25].
In general, it is substantially easier, less stressful, and less invasive to collect saliva than a
blood sample from feline patients. In addition, it does not need much expertise. However,
both venipuncture and saliva collection could be a challenge in some cats without sedation,
particularly in the feral cat populations targeted in seroepidemiological studies [26]. The
aim of this study was to detect and compare antibodies against B. henselae IFA antigens in
paired serum and OF specimens from cats.
2. Results
2.1. Description of the Study Cats
All the cats were European domestic short hair. Sixty-seven of 118 (56.8%) were female
and 51 (43.2%) were male cats. Their ages ranged from 4 months to 7 years, with a median
age of 1.7 years. For statistical analyses, cats ≤ 2 years old were considered young cats
and >2 years old were considered old cats. One hundred and sixteen of 118 (98.3%) were
sexually intact at the time of entry into the study. Shelter and client-owned cats comprised
55.1% (65/118) and 44.9% (53/118), of the study population, respectively. Owned cats
ranged in age from 5 months to 7 years, with a median age of 2.4 years. Shelter cats ranged
in age from 4 month to 5 years, with a median age of 1.2 years. Shelter cats were more likely
to be young cats (73.8%) when compared with old cats (37.7%) (Chi square test: X2 = 15.59,
df = 1, p < 0.001). History of tick and flea infestations were reported in 56.8% (67/118) of
the cats, while 19.5% (23/118) were flea-infested at the time of sampling (21 shelter cats
and two client-owned cats). Shelter cats were more likely to have a history of tick and/or
flea infestation (100%), when compared with client-owned cats (3.8%) (Fisher exact test,
p < 0.001). Routine treatment with ectoparasiticides was only reported for 25 client-owned
cats, 21.2% (25/118) of total cats. One hundred cats (84.7%) were assessed as clinically
healthy, whereas 18 (15.3%) cats had clinical signs with gingivitis being the most frequent
clinical sign found in nine sick cats (50%).
2.2. Inhouse Versus Commercial IFA Testing of Cat Sera
Considering antibody titers ≥ 1:64, 78% (92/118) cats were B. henselae seroreactive
when tested using both the inhouse and commercial IFA assays (Figure 1). The B. henselae
serum IFA geometric mean titer was 1:2088 with minimum and maximum titers of 1:64 and
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1:16,384, respectively. Bartonella henselae antibody titers ranged from 1:64 to 1:512 in 35.9%
(33/92) and >512 in 64.1% (59/92) of the seroreactive cats.
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Figure 1. Comparison of the proportion of IFA positive results in serum and OF specimens for
the detection of antibodies against B. henselae antigens. Abbreviations: IFA, immunofluorescence
antibody assay.
hen considering antibody titers ≥1:64 for the 118 cats in this study, Kappa agreement,
was almost perfect when comparing the inhouse IFA and the commercial IFA kit (Cohen’s
k = 1; 95% confident interval) (Table 1).
Table 1. Comparison of IFA agreement in serum and OF samples.
Test Pair κ ± SE κ Interpretation a
Inhouse IFA serum versus
commercial IFA serum 1 ± 0.000 Almost perfect agreement
Commercial IFA serum versus
commercial IFA O 0.429 ± 0.068 oderate agreement
Commercial IFA serum versus
commercial modified IFA OF 0.541 ± 0.072 Moderate agreement
a The interpretation for each κ value is shown in the final column according to the following scale: ≤0, no
agreement; 0.01–0.20, none to slight; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, substantial; and 0.81–1.00,
almost perfect agreement. Abbreviations: IFA, immunofluorescence antibody assay; OF, oral fluid; κ, Cohen’s
kappa v lue; SE, standard error.
There was moderate Kappa agreement (Kappa = 0.587; 95% confidence interval) when
comparing negative, low positive and high positive inhouse IFA antibody titers with the
fluorescence intensity for the commercial IFA (Figure 2). Based upon comparative analysis,
shelter cats were more likely to have serum B. henselae antibodies (100%) when compared
with client-owned cats (50.9%) (Fisher exact test, p < 0.001) (Table 2). Furthermore, shelter
cats were more likely to have high serum antibody titers (>1:512.) against B. henselae
(69.3%) when compared with client-owned cats (26.4%) (Chi square test: X2 = 42.99, df = 2,
p < 0.001). When age was considered, cats ≤ 2 years were more likely to be B. henselae
seroreactive (98.5%) than cats >2 years (50%) of age (Fisher’s exact test: p = 0.001).
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Table 2. Comparison of demographic and clinical variables among cats based upon the proportion of commercial IFA B.
henselae seroreactors in serum and OF.
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(n = 95) p Value
Serum 50.9% 100% <0.001 * 98.5% 50% <0.001 * 79.1% 76.5% 0.732 * 75% 94.4% 0.118 ** 100% 72.6% 0.004 **
OF 20.7% 72.3% <0.001 * 64.7% 28% <0.001 * 52.2% 45.1% 0.442 * 45% 72.2% 0.086 * 78.3% 42.1% 0.002 **
IFA: immunofluorescence antibody assay. n: number. OF: oral fluid. * Chi-square test; ** Fisher’s exact test; a significant association was
deduced when p < 0.05.
2.3. Commercial IFA in Serum and OF Samples
Using the commercial IFA, 78% (92/118) of cats were B. henselae seroreactive. All
cats B. henselae seronegative in both IFA assays were also negative in the OF IFA assay
(26/118). When seroreactivity results were categorized using specific fluorescence intensity
as the criteria described in Figure 2, 22% (26/118) of cats were seronegative, 15.3% (18/118)
were low positives and 62.7% (74/118) were high positives. Only 49.2% (58/118) of cat OF
samples were B. henselae antibody positive prior to the sample concentration step. When
comparing serum and OF samples, there was moderate Kappa agreement for detection of
B. henselae antibodies, using the commercial IFA assay (Cohen’s k = 0.429; 95% confidence
interval) (Table 1). Considering the end point inhouse IFA titer results, OF samples were
more likely to be positive in cats with high B. henselae serum antibody titers (>1:512) (77.2%)
when compared with low antibody titers (≤1:512) (22.8%) (Fisher’s exact test: P = 0.001).
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Comparisons between commercial serum and OF IFA results, when categorized as low
positive or high positive based upon inhouse IFA antibody titers are provided in Table 3.
Oral fluid antibodies were also more frequently found in young cats (≤2 years old) (64.7%),
compared to older cats (>2 years old) (28%) (Chi square test: X2 = 18.87, df = 1, p < 0.001).
The statistical comparison of the proportions of positive results based on clinical parameters
in both serum and OF samples are listed in Table 2. Serum and OF antibody titers did not
differ between sick cats with gingivitis and the rest of the sick and healthy cats. However,
all sick cats with gingivitis were seroreactive and seven of nine cats with gingivitis were
OF positives. Six gingivitis cats had serum antibody titers ≥1:512.
Table 3. Comparison between commercial B. henselae IFA results in serum and OF, when categorized
as low positive and high positive to the serum inhouse antibody IFA titer results.




Serum OF (Total) *




11 22 8 5
High positive >512
(n = 59) 8 51 19 26
Total (n = 92) 19 73 27 31
* Total OF results including commercial modified IFA. Abbreviations: IFA, immunofluorescence antibody assay;
n, number; OF, oral fluid.
2.4. Modified Commercial IFA Testing of OF Specimens
Fifty-two of 60 available B. henselae antibody OF negative samples and 10 antibody
OF positive samples were retested using the modified IFA. All previously positive IFA OF
samples remained B. henselae positive, 9 of 52 previously IFA negative samples became IFA
positive. In total 56.8% (67/118) of OF samples were B. henselae antibody reactive when
tested by both IFA assays. Of the 92 B. henselae seroreactors, 67 (72.8%) were OF antibody
positive. Comparison of the proportions of positive results in serum and OF using the two
IFA assays are shown in Figure 1. There was moderate Kappa agreement for detection of B.
henselae antibodies, when comparing total results obtained in serum and OF samples using
the commercial (not modified) and modified IFA assays (Table 1, Cohen’s k = 0.541; 95%
confidence interval).
3. Discussion
Although several studies have documented the presence of Bartonella spp. DNA in
oral samples obtained from cats [20,27,28], to the best of our knowledge, studies reporting
the presence of B. henselae antibodies in OF samples have not been published. Among the
92 B. henselae seroreactors in this study, only 67 (72.8%) were also OF antibody positive.
In agreement with our findings, a previous study determined that total IgG was lower
in oral samples when compared with serum samples [29]. To collect the OF samples,
we used cotton swabs soaked with hypertonic NaCL 7.5% to increase oral transudation
and salivation. Therefore, we obtained a higher volume of OF; however, it is possible
that the OF antibody concentration was diluted by the saline soaking of the swabs. In a
study investigating total IgG using ELISA, higher OF immunoglobulin concentrations were
obtained using unstimulated samples (dry swabs) [29]. Unfortunately, it was not possible
in the present study to collect OF samples with dry swabs, likely due to an inhibitory effect
of the anesthetic drugs on the production of OF. In order to increase IFA OF sensitivity, we
used the commercial IFA with modifications, which resulted in 9 out of 52 negative samples
being positive. It is possible that detection of B. henselae antibodies in OF specimens could
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be improved by concentrating saliva samples and thereby increasing the overall and B.
henselae-specific antibody concentrations. Consistent with this concept, a recent study
focused on the IgG purification of human saliva in order to achieve a high similarity of IgG
antibody profiles from blood and saliva for diagnostic testing purposes [30].
In the present study, there were no statistical differences in B. henselae seroreactivity
among cats with gingivitis compared to the rest of all cats, which is in agreement with
previous studies [31,32]. However, all sick cats with gingivostomatitis in this study were
B. henselae seroreactive and the majority were OF positive as well. High antibody titers
were reported in a previous study that established a relationship between oral lesions and
B. henselae and Bartonella clarridgeiae antibodies [21]. The results of this study differ from
studies involving FIV seropositive cats [26] and cats with chronic gingivostomatitis [29]. FIV
seropositive cats had increased salivary IgG levels, but this result was partly attributable to
the presence of oral inflammatory lesions as suggested by the higher ratios of salivary IgG
than serum IgG in both FIV seronegative and seropositive cats with oral lesions compared to
cats without oral lesions [26]. Similarly, cats with chronic gingivostomatitis had significantly
higher salivary IgM and IgG, but significantly lower salivary IgA concentrations than
healthy cats [33]. In contrast, higher salivary IgA and lower IgM and IgG were reported
in healthy cats using ELISA and single radial immunodiffusion (SRID) assays [29]. In
addition to the clinical status (healthy vs. sick for gingivostomatitis) of the cat, variable
results in detection of antibodies may be due to the use of different diagnostic techniques,
IFA and Western blot had also been used as immunoglobulin diagnostic techniques for
OF [24]. In dogs, similar concentrations of anti-Leishmania IgG2 antibodies were found
in serum and saliva measured by time-resolved immunofluorometric assays (TR-IFMAs),
likely due to the high sensitivity of this assay [34].
Because of many factors, IFA assays could be considered subjective techniques, in-
cluding the skills and experience of the technologist in results interpretation, antibody
cross-reactions, and antigen sources used. These and other factors influence IFA sensitivity
and specificity. In this study, we found identical seroreactivity results using inhouse and
commercial B. henselae IFA assays. Furthermore, there was moderate agreement when
comparing antibody intensity categories in the commercial assay to inhouse IFA antibody
titers. Although it is necessary to develop more studies focused on the determination and
measuring of antibodies in OF or saliva as a diagnostic technique, recently published OF
optimization studies performed in other infections [24,29] could indicate that B. henselae
OF could provide an efficient alternative to serum. Despite the low sensitivity of OF when
compared with serum, OF noninvasive specimens could be an important resource for
antibody detection procedures in cats and other animals from whom blood collection is
challenging. In the present study, swabs were maintained in the mouth for 3−4 min but it
is likely that with less time similar results will be obtained. Therefore, further OF collection
and sample processing studies are needed to enhance the sensitivity of OF for Bartonella
spp. antibody detection diagnosis in cats.
In this study, the very high B. henselae seroprevalence indicates that infection with
Bartonella is common among shelter cats with high ectoparasite exposure in areas around
Barcelona. Others studies involving cats from Spain have reported Bartonella spp. sero-
prevalence rates of 23.8% (Madrid) [35], 29.6% (Catalonia) [36], 35.3% (Catalonia) [37], and
71.4% (Catalonia and Mallorca Island) [38]. Seroprevalence differences between Spanish
studies likely relate to the source of the cats, with higher risk being associated with stray
and shelter cats because of extensive flea exposure and lack of prophylaxis. This study is in
agreement with evolving evidence that cats living in the Mediterranean region have higher
Bartonella spp. prevalence than others areas in Spain and Europe [4].
4. Materials and Methods
4.1. Cats
One hundred and eighteen cats from Barcelona province (Spain) were enrolled into
the study between 2017 and 2019. A clinical questionnaire was completed for each cat
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including information about age, breed, sex, shelter/client-owned, health status (sick
versus healthy), presence of fleas and /or ticks, or bites and the use of acaricide products.
For all cats, a complete physical examination was performed by a veterinarian. In most
cases (n = 110), blood specimens were obtained under general anesthesia during a routine
neutering procedure.
4.2. Serum Specimens
For each cat at the time of enrollment, peripheral blood was collected by jugular or
cephalic venipuncture, with 4–6 mL placed in serum tubes containing a clot accelerator
and granule serum separator (Aquisel, Barcelona, Spain). These samples were centrifuged
at 790× g for 10 min (Heraeus Labofuge 400R, Thermo Fisher Scientific, Waltham, MA,
USA) to obtain the serum that was stored at −80 ◦C until used.
4.3. Oral Fluid Specimens
To obtain the OF, a swab (Ecouvillon PP, Dominique Dutscher, Bernolsheim, France)
was soaked with hypertonic NaCL 7.5%. (B. Braun Melsungen AG, Melsungen, Germany)
to obtain oral transudation and salivation. The swap was placed into the cat’s mouth
between the gum and the inner mucosa of the upper or lower lip. To obtain the OF sample
for antibody testing, the swab was maintained in that position for 3−4 min, after which
the swab head was placed in an Eppendorf tube and centrifuged at 16000× g for 10 min
(Eppendorf Centrifuge 5418, Merck KGaA, Darmstadt, Germany). OF samples were stored
at −80 ◦C until tested.
4.4. Bartonella henselae Inhouse IFA Serological Testing
Initially, the 118 cat sera were tested at North Carolina State University, Intracellular
Pathogens Research Laboratory using a previously inhouse B. henselae IFA assay for end
point antibody titration [15,38] with some modifications and validated in dogs [7]. Briefly,
to obtain antigens for IFA testing, B. henselae SA2+ (feline origin Missy 95 FO-099), was
passed from agar grown cultures into DH82 (a continuous canine histiocytic cell line)
cultures. Heavily infected cell cultures were spotted onto 30-well Teflon-coated slides
(Cel-Line/Thermo Scientific), air-dried, acetone-fixed, and stored frozen. Serum samples
were diluted in phosphate buffered saline (PBS) solution containing 1% normal goat serum,
0.05% Tween-20 and 0.5% powdered nonfat dry milk (BioRad, Hercules, CA, USA) to block
non-specific antigen binding sites. Patient sera were further tested with 2-fold dilutions out
to a final dilution of 1:16,384 and 10 µL of every serum dilution was applied per well. The
slides were incubated for 30 min at 37 ◦C and washed with PBS under moderate agitation
for another 30 min. Once slides were dry, 10 µL of fluorescein-conjugated goat IgG anti-cat
(MP biomedicals, Irvine, CA, USA) at dilution of 1:100 was added into each well. The
slides were incubated for another 30 min at 37 ◦C in the dark to protect the photosensitive
conjugate. The washing procedure described above was repeated adding a few drops of
Tween 20. After the last washing procedure, some drops of mounting medium (Vectashield,
Burlingame, CA, USA) were added on the cover slips. The slides were evaluated using a
fluorescence microscope (OPTIKA Fluo B-383, OptikaItaly, Ponteranica, Italy) at 200× and
400× magnification and each well was compared to the fluorescence pattern seen in the
positive and negative controls. To avoid confusion with possible nonspecific binding found
at low dilutions, a cutoff of 1:64 was selected as a seroreactive antibody titer [38]. Cats were
considered seronegative at titers <1:64. For statistical comparisons, cats were categorized
as low antibody positive for titers between 1:64 and 1:512 and high antibody positive for
titers >1:512. Experimental infection studies in cats have documented that the geometric
mean of maximum antibody titer peak was ≥1:512 [15,39]. Moreover, previous studies in
dogs and humans have classified antibody titers of ≥1:512 as high positives [40,41].
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4.5. Bartonella henselae Commercial IFA Paired Serological and OF Testing
An indirect immunofluorescence assay (MegaFLUO B. henselae, Diagnostik Megacor,
Hörbranz, Austria) for the detection of IgG antibody against B. henselae antigens was
performed on paired sera and OF samples. Immunofluorescence antibody assay was per-
formed for all cats included in this study at the Autonomous University of Barcelona. The
serum samples were diluted to 1:64 with PBS while OF samples were not diluted. Twenty
microliters of every paired sample, diluted serum and not diluted OF from the same cat,
were applied in different wells in the same slide. The slides were incubated for 30 min at
37 ◦C. After that, a washing procedure was performed. The slides were washed twice with
PBS for 5 min and once with distilled water. After the washing procedure described, 15 µL
of FLUO FITC anti-cat IgG conjugate was added into each well. The slides were incubated
for another 30 min at 37 ◦C in the dark to protect the photosensitive conjugate. The washing
procedure described above was repeated. After the second washing procedure, some drops
of mounting medium were added on the cover slips. The slides were evaluated using a
fluorescence microscope (Leica DM6000 B; Leica Microsystems, Wetzlar, Germany) at 200×
and 400× magnification and each well was compared to the fluorescence pattern seen in
the positive and negative controls. All samples were examined by two different investiga-
tors to avoid observer error. Serum samples that were not fluorescent at a 1:64 titer were
considered seronegative according to the manufacturers’ instructions and as previously
described [42,43]. To compare OF versus serum antibody reactivity, the intensity of the
specific organism (B. henselae) fluorescence observed was used as subjective criteria for
classifying antibody concentration into negative, low positive and high positive (Figure 2).
Due to economic restrictions, endpoint antibody titration was not performed with B. hense-
lae commercial IFA whereas serum antibody titration was determined by the inhouse IFA.
4.6. Modified B. henselae Commercial IFA OF Testing
For the 52 of the 60 OF samples that were B. henselae-antibody negative, a modified
IFA assay was performed. There was inadequate volume to retest eight OF negative
samples. The modified IFA procedure was performed for 10 previously OF positive
samples and 52 OF negative samples. The objective of this modification was to determine
if B. henselae OF antibodies could be detected by adding double the volume of the OF. Thus
the modified commercial IFA used 40 µL of OF instead 20 µL. Indirect immunofluorescence
assay (MegaFLUO B. henselae, Diagnostik Megacor, Hörbranz, Austria) for the detection of
specific IgG antibody against B. henselae antigens was performed by adding a second OF
sample incubation step. Following the protocol described above, after the first washing
procedure, another 20 µL of nondiluted OF sample was applied in the same well of first
incubation, after which the slide was incubated again for 30 min at 37 ◦C. The rest of the
commercial IFA protocol was followed without modification and the results were read as
described above using classification criteria shown in Figure 2.
4.7. Statistical Analysis
The cumulative data collected from each cat, as well as the B. henselae antibody de-
tection, in paired serum and OF samples were evaluated statistically. Frequency analysis
for age, sex, stray/client-owned, ectoparasites, healthy status and the different IFA assays
results was assessed. Comparative analysis of categorical data was performed by using
chi-square test or Fisher’s exact test. The kappa (k) statistic was used to assess the degree of
(interrater) agreement between end point inhouse IFA results and commercial IFA results
classified using the subjective criteria described in Figure 2. Kappa was used also to assess
the degree of agreement between commercial IFA used to test serum and OF samples. The
following interpretation of the k statistic was: k < 0 poor, k = 0–0.2 slight, k = 0.21–0.4 fair,
k = 0.41–0.6 moderate, k = 0.61–0.8 substantial, k = 0.81–1 almost perfect agreement. A
significant association was deduced when p < 0.05. The statistical analysis was performed
using the R program i386 version 3.6.1 (R Development Core Team) (R Foundation for
Statistical Computing, Vienna, Austria) and the Deducer R program version 1.7–16 (De-
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ducer: a data analysis GUI for R) (R Foundation for Statistical Computing company, Vienna,
Austria) for Windows software.
5. Conclusions
In conclusion, OF antibodies were more likely to be detected in cats with high B. hense-
lae serum antibody titers. When compared with sera in this study, measuring B. henselae
OF antibodies by IFA testing was less sensitive. Therefore, without further successful
optimization of Bartonella spp. antibody detection, OF specimens do not appear to be an
adequately sensitive epidemiological or diagnostic assay for testing cats. In the context of
test reproducibility, the inhouse and commercial IFA assays generated identical seroreactive
and seronegative results for the 118 cats in this study.
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BAPGM Bartonella Alpha-Proteobacteria Growth Medium
B. henselae Bartonella henselae
ELISA Enzyme-linked immunosorbent assay
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IFA Immunofluorescence antibody assay
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